Pediatric Acute Leukemia Inititative
PedAL is a collaborative effort sponsored by the Leukemia & Lymphoma Society to enable a precision medicine approach to pediatric relapsed, refractory, and high risk leukemias. By changing the paradigm for pediatric leukemia clinical trials to one that is internationally integrated and collaborative, PedAL aims to accelerate the testing of new precision medicine therapies and change how we develop novel, targeted therapies in the treatment of children with relapsed leukemia.
The centerpiece of PedAL is an integrated multi-site, multi-therapy Master Clinical Trial. By creating a new, collaborative model for pediatric leukemia clinical trials PedAL will support the creation of the regulatory and technical infrastructure for data aggregation and sharing. The aims of this new model include creating operational and cost efficiencies in study management, making data from different sources interoperable, easily identifying appropriate patients for new therapies, and consolidating clinical and scientific data from institutes and consortia nationwide.